A Phase 1 interventional study of Avastin and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-04.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 114th largest by enrollment of the 183 interventional ones that give a count, is one of 15 that started in 2005, is one of 29 in phase 1, and was the 77th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–70
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 40 · Phase 4 5
First in 1998; this study’s year is marked. 15 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 50 across the 183 interventional studies. Of the 134 that completed or were terminated, 35 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 206 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 64th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2005, is one of 22 in phase 1, and was the 18th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
4 of the studies testing oxaliplatin in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will investigate possible pharmacokinetic interactions between Xeloda and oxaliplatin, and assess whether the pharmacokinetics of Xeloda and/or oxaliplatin is influenced by the addition of Avastin. All subjects will provide samples for pharmacokinetic analysis during the first 3 cycles of treatment. In cycles 1 and 2 patients will receive a treatment regimen containing Xeloda (1000mg/m2 bid) and oxaliplatin (130mg/m2 iv) and in cycle 3 Avastin (7.5mg/kg iv) will be added to the regimen. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avastin · Drug: Oxaliplatin · Drug: capecitabine [Xeloda]
7.5mg/kg iv (cycle 3 only)
130mg/m2 iv (cycles 1, 2 and 3)
1000mg/m2 po bid (cycles 1, 2 and 3)
Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR)
AUC0-infinity represents the area under the concentration-time curve of the analyte (5'-DFUR) in plasma over the time interval from 0 extrapolated to infinity. The analyte 5'-DFUR, the direct precursor of 5-fluorouracil (5-FU), is considered to be the most important metabolite of capecitabine in plasma. The unit of measure was nanograms per millilitre per hour (ng/mL \* hr).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose.
AUC0-inf for Free Platinum
AUC0-infinity represents the area under the concentration-time curve of the analyte (free platinum) in plasma over the time interval from 0 extrapolated to infinity. AUC0-inf for free platinum was calculated for each participant from the concentration-data obtained on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3. Free platinum is not bound to plasma proteins and is considered to be the most clinically significant measure of pharmacological and toxicological activity.
Time frame: Predose , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the 2 hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
AUC (0-infinity) of Capecitabine and Its Metabolites (5'-DFCR, 5-FU, and FBAL)
AUC0-infinity represents the area under the concentration-time curve of the analytes (5'-DFCR, 5-FU, and FBAL) in plasma over the time interval from 0 extrapolated to infinity. After oral administration, capecitabine is first metabolized in the liver to 5'-deoxy-5-fluorocytidine (5'-DFCR), which is then converted to 5'-DFUR, and then catalytically activated to 5-FU.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
AUC0-last of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Maximum Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
Cmax is defined as maximum observed analyte concentration of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Elimination Half-life Period (t1/2 Beta) of Capecitabine and Its Metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)
t1/2 Beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of capecitabine and its metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
AUC0-infinity for Total Platinum
AUC0-infinity represents the area under the concentration-time curve of the analyte (total platinum) in plasma over the time interval from 0 extrapolated to infinity.
Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
AUC0-last of Total And Free Platinum
Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of Total And Free Platinum.
Time frame: pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
Cmax of Total And Free Platinum
Cmax is defined as maximum observed analyte concentration of Total And Free Platinum.
Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
T1/2 Beta of Total And Free Platinum
T1/2 beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of total and free platinum.
Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
Volume of Distribution at Steady State (VSS) of Total And Free Platinum
VSS is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours
Clearance of Total And Free Platinum
CL is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (hour).
Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
Number Of Participants With Adverse Events (AEs)
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. This includes any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during the study were also to be reported as AEs.
Time frame: Approximately 3 Years (up to 28 days after the last intake of study medication)
Marked Laboratory Abnormalities
Number of participants with marked laboratory abnormalities (hematology, coagulation, liver function, renal function, protein, electrolytes, miscellaneous).
Time frame: Up to 28 days after last chemotherapy administration
A total of 36 participants were enrolled in this study at three sites in Canada between 8 August 2005 and 24 April 2008.
| Milestone | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Started | 36 |
| Completed | 7 |
| Not completed | 29 |
| Withdrew: Adverse event | 8 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Insufficient therapeutic response | 13 |
| Withdrew: Progression | 1 |
| Withdrew: Surgery | 4 |
| Withdrew: Break from chemotherapy | 1 |
AUC0-infinity represents the area under the concentration-time curve of the analyte (5'-DFUR) in plasma over the time interval from 0 extrapolated to infinity. The analyte 5'-DFUR, the direct precursor of 5-fluorouracil (5-FU), is considered to be the most important metabolite of capecitabine in plasma. The unit of measure was nanograms per millilitre per hour (ng/mL \* hr).
| ng/mL*hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Cycle 1, Day 1 | 13605 ± 33 |
| Cycle 2, Day 1 | 12177 ± 27 |
| Cycle 3, Day 1 | 11817 ± 38 |
AUC0-infinity represents the area under the concentration-time curve of the analyte (free platinum) in plasma over the time interval from 0 extrapolated to infinity. AUC0-inf for free platinum was calculated for each participant from the concentration-data obtained on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3. Free platinum is not bound to plasma proteins and is considered to be the most clinically significant measure of pharmacological and toxicological activity.
| ng/mL * hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Cycle 1, Day 2 | 10069 ± 23 |
| Cycle 2 , Day 1 | 10537 ± 24 |
| Cycle 3, Day 1. | 10225 ± 23 |
AUC0-infinity represents the area under the concentration-time curve of the analytes (5'-DFCR, 5-FU, and FBAL) in plasma over the time interval from 0 extrapolated to infinity. After oral administration, capecitabine is first metabolized in the liver to 5'-deoxy-5-fluorocytidine (5'-DFCR), which is then converted to 5'-DFUR, and then catalytically activated to 5-FU.
| ng/mL*hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Capcetabine , Cycle 1, Day 1 | 5217 ± 57 |
| Capcetabine , Cycle 2, Day 1 | 5299 ± 54 |
| Capcetabine , Cycle 3, Day 1 | 6130 ± 68 |
| 5'-DFCR , Cycle 1, Day 1 | 7630 ± 76 |
| 5'-DFCR , Cycle 2, Day 1 | 6409 ± 47 |
| 5'-DFCR, Cylce 3, Day 1 | 7989 ± 52 |
| 5-FU , Cycle 1, Day 1 | 437 ± 92 |
| 5-FU , Cycle 2, Day 1 | 355 ± 50 |
| 5-FU , Cycle 3, Day 1 | 343 ± 86 |
| FBAL , Cycle 1, Day 1 | 17904 ± 27 |
| FBAL , Cycle 2, Day 1 | 17413 ± 26 |
| FBAL , Cycle 3, Day 1 | 17356 ± 34 |
Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL).
| ng/mL*hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| 5' DFUR , Cycle 1, Day 1 | 13503 ± 33 |
| 5' DFUR, Cycle 2 , Day 1 | 12057 ± 28 |
| 5' DFUR, Cycle 3, Day 1 | 11618 ± 38 |
| Capecitabine, Cycle 1, Day 1 | 5201 ± 57 |
| Capecitabine, Cycle 2, Day 1 | 5273 ± 54 |
| Capecitabine, Cycle 3, Day 1 | 6093 ± 68 |
| 5'-DFCR, Cycle 1, Day 1 | 6150 ± 80 |
| 5'-DFCR, Cycle 2 , Day 1 | 6378 ± 47 |
| 5'-DFCR, Cycle 3, Day 1 | 7909 ± 52 |
| 5-FU, Cycle 1, Day 1 | 433 ± 92 |
| 5-FU, Cycle 2, Day 1 | 350 ± 51 |
| 5-FU, Cycle 3, Day 1 | 336 ± 84 |
| FBAL, Cycle 1, Day 1 | 16773 ± 26 |
| FBAL, Cycle 2, Day 1 | 15992 ± 26 |
| FBAL, Cycle 3, Day 1 | 14947 ± 31 |
Cmax is defined as maximum observed analyte concentration of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
| ng/mL | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| 5'-DFUR, Cycle 1, Day 1 | 8847 ± 48 |
| 5'-DFUR , Cycle 2, Day 1 | 6545 ± 48 |
| 5'-DFUR , Cycle 3, Day 1 | 5693 ± 54 |
| Capecitabine, Cycle 1, Day 1 | 4930 ± 72 |
| Capecitabine, Cycle 2, Day 1 | 4065 ± 73 |
| Capecitabine, Cycle 3, Day 1 | 4167 ± 81 |
| 5' DFCR, Cycle 1, Day 1 | 3902 ± 78 |
| 5' DFCR, Cycle 2, Day 1 | 3407 ± 66 |
| 5' DFCR , Cycle 3, Day 1 | 3747 ± 69 |
| 5-FU, Cycle 1 , Day 1 | 292 ± 63 |
| 5-FU, Cycle 2, Day 1 | 216 ± 63 |
| 5-FU, Cycle 3, Day 1 | 168 ± 83 |
| FBAL, Cycle 1, Day 1 | 3970 ± 19 |
| FBAL, Cycle 2, Day 1 | 3627 ± 27 |
| FBAL, Cycle 3, Day 1 | 3292 ± 34 |
t1/2 Beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of capecitabine and its metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)
| hour | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| 5' DFUR; Cycle 1, Day 1 | 0.65 ± 19 |
| 5' DFUR, Cycle 2 , Day 1 | 0.64 ± 49 |
| 5' DFUR, Cycle 3, Day 1 | 0.75 ± 39 |
| Capecitabine, Cycle 1, Day 1 | 0.37 ± 52 |
| Capecitabine, Cycle 2, Day 1 | 0.51 ± 55 |
| Capecitabine, Cycle 3, Day 1 | 0.56 ± 42 |
| 5'-DFCR, Cycle 1, Day 1 | 0.71 ± 33 |
| 5'-DFCR, Cycle 2 , Day 1 | 0.75 ± 32 |
| 5'-DFCR, Cycle 3, Day 1 | 0.79 ± 24 |
| 5-FU, Cycle 1, Day 1 | 0.61 ± 20 |
| 5-FU, Cycle 2, Day 1 | 0.67 ± 61 |
| 5-FU, Cycle 3, Day 1 | 0.71 ± 31 |
| FBAL, Cycle 1, Day 1 | 2.77 ± 19 |
| FBAL, Cycle 2, Day 1 | 2.68 ± 26 |
| FBAL, Cycle 3, Day 1 | 2.64 ± 33 |
AUC0-infinity represents the area under the concentration-time curve of the analyte (total platinum) in plasma over the time interval from 0 extrapolated to infinity.
| ng/mL* hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Cycle 1, Day 2 | 139329 ± 24 |
| Cycle 2, Day 1 | 167610 ± 17 |
| Cycle 3, Day 1 | 186268 ± 21 |
Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of Total And Free Platinum.
| ng/mL* hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Total Platinum: Cycle 1, Day 2 | 85406 ± 20 |
| Total Platinum: Cycle 2, Day 1 | 97083 ± 12 |
| Total Platinum: Cycle 3, Day 1 | 97011 ± 17 |
| Free Platinum: Cycle 1, Day 2 | 9399 ± 24 |
| Free Platinum: Cycle 2, Day 1 | 9818 ± 25 |
| Free Platinum: Cycle 3, Day 1 | 9604 ± 22 |
Cmax is defined as maximum observed analyte concentration of Total And Free Platinum.
| ng/mL | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Total Platinum: Cycle 1, Day 2 | 3652 ± 14 |
| Total Platinum: Cycle 2, Day 1 | 3741 ± 19 |
| Total Platinum: Cycle 3, Day 1 | 3706 ± 21 |
| Free Platinum: Cycle 1, Day 2 | 1818 ± 27 |
| Free Platinum: Cycle 2, Day 1 | 1840 ± 36 |
| Free Platinum: Cycle 3, Day 1 | 1813 ± 30 |
T1/2 beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of total and free platinum.
| hour | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Total Platinum: Cycle 1, Day 2 | 48.70 ± 30 |
| Total Platinum: Cycle 2, Day 1 | 55.73 ± 24 |
| Total Platinum: Cycle 3, Day 1 | 67.28 ± 26 |
| Free Platinum: Cycle 1, Day 2 | 17.64 ± 10 |
| Free Platinum: Cycle 2, Day 1 | 18.41 ± 9 |
| Free Platinum: Cycle 3, Day 1 | 18.47 ± 10.90 |
VSS is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
| mL | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Total Platinum: Cycle 1, Day 2 | 109007 ± 23 |
| Total Platinum: Cycle 2, Day 1 | 105097 ± 21 |
| Total Platinum: Cycle 3, Day 1 | 112141 ± 21 |
| Free Platinum: Cycle 1, Day 2 | 387158 ± 23 |
| Free Platinum: Cycle 2, Day 1 | 389193 ± 29 |
| Free Platinum: Cycle 3, Day 1 | 401040 ± 24 |
CL is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (hour).
| mL/Hr | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Total Platinum: Cycle 1, Day 2 | 1603 ± 78 |
| Total Platinum: Cycle 2, Day 1 | 1331 ± 22 |
| Total Platinum: Cycle 3, Day 1 | 1198 ± 25 |
| Free Platinum: Cycle 1, Day 2 | 22183 ± 23 |
| Free Platinum: Cycle 2, Day 1 | 21176 ± 26 |
| Free Platinum: Cycle 3, Day 1 | 21823 ± 23 |
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. This includes any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during the study were also to be reported as AEs.
| Participants | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Any AE | 36 |
| Any SAE | 16 |
Number of participants with marked laboratory abnormalities (hematology, coagulation, liver function, renal function, protein, electrolytes, miscellaneous).
| Participants | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Hematocrit - high | 2 |
| Hematocrit - low | 5 |
| Hemoglobin - low | 6 |
| Platelets - high | 1 |
| Platelets - low | 9 |
| RBC - low | 12 |
| WBC - high | 1 |
| WBC - low | 7 |
| Neutrophils - high | 1 |
| Neutrophils - low | 3 |
| PT (INR) - high | 2 |
| ASAT (SGOT) - high | 6 |
| LDH - high | 2 |
| ALAT (SGPT) - high | 7 |
| Alk. Phos. - high | 6 |
| Dir. Bilirubin - high | 3 |
| Total Bilirubin - high | 2 |
| Creatinine - high | 0 |
| Albumin - low | 4 |
| Potassium - low | 2 |
| Sodium - low | 2 |
| Calcium - low | 1 |
| Glucose Fasting - high | 4 |
Collected over Approximately 3 Years (up to 28 days after the last intake of study medication). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine+ Oxaliplatin+ Bevacizumab | — | 16/36 (44.4%) | 36/36 (100%) |
| Event | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| DehydrationMetabolism and nutrition disorders | 6/36 |
| DiarrhoeaGastrointestinal disorders | 4/36 |
| PyrexiaGeneral disorders | 3/36 |
| Abdominal painGastrointestinal disorders | 2/36 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/36 |
| NeutropeniaBlood and lymphatic system disorders | 2/36 |
| EnteritisGastrointestinal disorders | 1/36 |
| Intestinal obstructionGastrointestinal disorders | 1/36 |
| VomitingGastrointestinal disorders | 1/36 |
| PainGeneral disorders | 1/36 |
| Event | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| FatigueGeneral disorders | 32/36 |
| NauseaGastrointestinal disorders | 30/36 |
| DiarrhoeaGastrointestinal disorders | 29/36 |
| Peripheral sensory neuropathyNervous system disorders | 22/36 |
| VomitingGastrointestinal disorders | 21/36 |
| Palmar-plantarSkin and subcutaneous tissue disorders | 20/36 |
| AnorexiaMetabolism and nutrition disorders | 20/36 |
| Abdominal painGastrointestinal disorders | 14/36 |
| Neuropathy peripheralNervous system disorders | 14/36 |
| NeutropeniaBlood and lymphatic system disorders | 11/36 |
| Age, Continuous(Years) | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Mean | 57.3 ± 13.03 |
| Sex: Female, Male(Participants) | Capecitabine+ Oxaliplatin+ Bevacizumab |
|---|---|
| Female | 21 |
| Male | 15 |
The record gives a start of Jul 2005, a primary completion of Sep 2006 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 9 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxaliplatin